Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000672119 | SCV000797186 | likely pathogenic | Pendred syndrome | 2018-01-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001386692 | SCV001587029 | pathogenic | not provided | 2023-12-12 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 421 of the SLC26A4 protein (p.Gln421Pro). This variant is present in population databases (no rsID available, gnomAD 0.005%). This missense change has been observed in individual(s) with SLC26A4-related conditions (PMID: 17718863, 23918157, 24224479, 28964290). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 556159). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV000770862 | SCV002026921 | likely pathogenic | Autosomal recessive nonsyndromic hearing loss 4 | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000672119 | SCV002026922 | likely pathogenic | Pendred syndrome | 2021-09-05 | criteria provided, single submitter | clinical testing | |
3billion | RCV000770862 | SCV002573167 | pathogenic | Autosomal recessive nonsyndromic hearing loss 4 | 2022-09-01 | criteria provided, single submitter | clinical testing | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.001%). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.94; 3Cnet: 0.97). Same nucleotide change resulting in same amino acid change (ClinVar ID: VCV000556159 ) and different missense changes at the same codon (p.Gln421Arg, p.Gln421Leu/ ClinVar ID: VCV000430229 , VCV000691513 ) have been previously reported as pathogenic/likely pathogenic with strong evidence. The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least one similarly affected unrelated individual (PMID: 23918157). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. |
Baylor Genetics | RCV000770862 | SCV004204222 | pathogenic | Autosomal recessive nonsyndromic hearing loss 4 | 2023-01-27 | criteria provided, single submitter | clinical testing | |
Genetic Testing Center for Deafness, |
RCV000770862 | SCV000902371 | likely pathogenic | Autosomal recessive nonsyndromic hearing loss 4 | 2019-02-26 | no assertion criteria provided | case-control |